The Capsule of Acinetobacter baumannii Protects against the Innate Immune Response

Acinetobacter baumannii is an opportunistic pathogen that has recently emerged as a global threat associated with high morbidity, mortality, and antibiotic resistance. We determined the role of type I interferon (IFN) signaling in A. baumannii infection. We report that A. baumannii can induce a type I IFN response that is dependent upon TLR4-TRIF-IRF3 and phagocytosis of the bacterium. Phase variants of A. baumannii that have a reduced capsule, lead to enhanced TLR4-dependent type I IFN induction. This was also observed in a capsule-deficient strain. However, we did not observe a role for this pathway in vivo. The enhanced signaling could be accounted for by increased phagocytosis in capsule-deficient strains that also lead to enhanced host cell-mediated killing. The increased cytokine response in the absence of the capsule was not exclusive to type I IFN signaling. Several cytokines, including the proinflammatory IL-6, were increased in cells stimulated with the capsule-deficient strain, also observed in vivo. After 4 h in our acute pneumonia model, the burden of a capsule-null strain was significantly reduced, yet we observed increases in innate immune cells and inflammatory markers compared to wild-type A. baumannii. This study underscores the role of phase variation in the modulation of host immune responses and indicates that the capsule of A. baumannii plays an important role in protection against host cell killing and evasion from activation of the innate immune response.

[1]  Adeline Peignier,et al.  Impact of Type I Interferons on Susceptibility to Bacterial Pathogens. , 2021, Trends in microbiology.

[2]  M. Adams,et al.  Capsule carbohydrate structure determines virulence in Acinetobacter baumannii , 2021, PLoS pathogens.

[3]  Adeline Peignier,et al.  Differential Induction of Type I and III Interferons by Staphylococcus aureus , 2020, Infection and Immunity.

[4]  Silvia Pires,et al.  Biological sex influences susceptibility to Acinetobacter baumannii pneumonia in mice. , 2020, JCI insight.

[5]  P. Rather,et al.  Extraction and Visualization of Capsular Polysaccharide from Acinetobacter baumannii. , 2019, Methods in molecular biology.

[6]  P. Rather,et al.  Role of Capsule in Resistance to Disinfectants, Host Antimicrobials, and Desiccation in Acinetobacter baumannii , 2018, Antimicrobial Agents and Chemotherapy.

[7]  Silvia Pires,et al.  IL‐1β activation in response to Staphylococcus aureus lung infection requires inflammasome‐dependent and independent mechanisms , 2018, European journal of immunology.

[8]  P. Rather,et al.  A high-frequency phenotypic switch links bacterial virulence and environmental survival in Acinetobacter baumannii , 2018, Nature Microbiology.

[9]  M. Zhu,et al.  Research and analysis of 74 bloodstream infection cases of Acinetobacter baumannii and drug resistance. , 2018, European review for medical and pharmacological sciences.

[10]  M. Ouellette,et al.  Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. , 2017, The Lancet. Infectious diseases.

[11]  M. Feldman,et al.  Uncovering the mechanisms of Acinetobacter baumannii virulence , 2017, Nature Reviews Microbiology.

[12]  R. Lai,et al.  Type I IFN operates pyroptosis and necroptosis during multidrug-resistant A. baumannii infection , 2018, Cell Death & Differentiation.

[13]  Ziwen Zhao,et al.  Pneumonia caused by extensive drug-resistant Acinetobacter baumannii among hospitalized patients: genetic relationships, risk factors and mortality , 2017, BMC Infectious Diseases.

[14]  R. Bonomo,et al.  Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges , 2016, Clinical Microbiology Reviews.

[15]  S. Smirnov,et al.  Distinct Roles of Type I and Type III Interferons in Intestinal Immunity to Homologous and Heterologous Rotavirus Infections , 2016, PLoS pathogens.

[16]  Yoon-Dong Park,et al.  Masking the Pathogen: Evolutionary Strategies of Fungi and Their Bacterial Counterparts , 2015, Journal of fungi.

[17]  P. Rather,et al.  Phase-Variable Control of Multiple Phenotypes in Acinetobacter baumannii Strain AB5075 , 2015, Journal of bacteriology.

[18]  I. Paulsen,et al.  Community-acquired Acinetobacter baumannii: clinical characteristics, epidemiology and pathogenesis , 2015, Expert review of anti-infective therapy.

[19]  R. Isberg,et al.  Antibiotic Modulation of Capsular Exopolysaccharide and Virulence in Acinetobacter baumannii , 2015, PLoS pathogens.

[20]  P. Higgins,et al.  Detection of pan drug-resistant Acinetobacter baumannii in Germany. , 2014, The Journal of antimicrobial chemotherapy.

[21]  Paolo Visca,et al.  Acinetobacter baumannii: evolution of a global pathogen. , 2014, Pathogens and disease.

[22]  A. Kaya,et al.  Ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii: risk factors, clinical features, and outcomes. , 2014, American journal of infection control.

[23]  Nichollas E. Scott,et al.  A common pathway for O‐linked protein‐glycosylation and synthesis of capsule in Acinetobacter baumannii , 2013, Molecular microbiology.

[24]  Francis J. Martin,et al.  Induction of type I interferon signaling by Pseudomonas aeruginosa is diminished in cystic fibrosis epithelial cells. , 2012, American journal of respiratory cell and molecular biology.

[25]  A. Prince,et al.  Staphylococcus aureus Induces Type I IFN Signaling in Dendritic Cells Via TLR9 , 2012, The Journal of Immunology.

[26]  M. Iacono,et al.  The genomics of Acinetobacter baumannii: Insights into genome plasticity, antimicrobial resistance and pathogenicity , 2011, IUBMB life.

[27]  Francis J. Martin,et al.  Streptococcus pneumoniae DNA Initiates Type I Interferon Signaling in the Respiratory Tract , 2011, mBio.

[28]  T. Umland,et al.  The K1 Capsular Polysaccharide of Acinetobacter baumannii Strain 307-0294 Is a Major Virulence Factor , 2010, Infection and Immunity.

[29]  S. Hammerschmidt,et al.  Toll-Like Receptor Stimulation Enhances Phagocytosis and Intracellular Killing of Nonencapsulated and Encapsulated Streptococcus pneumoniae by Murine Microglia , 2009, Infection and Immunity.

[30]  S. Grinstein,et al.  CD36 and TLR Interactions in Inflammation and Phagocytosis: Implications for Malaria1 , 2009, The Journal of Immunology.

[31]  G. Pier,et al.  The pgaABCD Locus of Acinetobacter baumannii Encodes the Production of Poly-β-1-6-N-Acetylglucosamine, Which Is Critical for Biofilm Formation , 2009, Journal of bacteriology.

[32]  G. Cheng,et al.  With a little help from my friends: modulation of phagocytosis through TLR activation , 2008, Cell Research.

[33]  R. Weinstein,et al.  Acinetobacter infection. , 2008, The New England journal of medicine.

[34]  L. Dijkshoorn,et al.  An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii , 2007, Nature Reviews Microbiology.

[35]  R. Darveau,et al.  MD-2 Mediates the Ability of Tetra-Acylated and Penta-Acylated Lipopolysaccharides to Antagonize Escherichia coli Lipopolysaccharide at the TLR4 Signaling Complex1 , 2005, The Journal of Immunology.

[36]  Jonathan R Edwards,et al.  Overview of nosocomial infections caused by gram-negative bacilli. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  R. Gaynes,et al.  NATIONAL NOSOCOMIAL INFECTIONS SURVEILLANCE S. OVERVIEW OF NOSOCOMIAL INFECTIONS CAUSED BY GRAM-NEGATIVE BACILLI , 2005 .

[38]  Ryan M. O’Connell,et al.  Toll-like Receptors Induce a Phagocytic Gene Program through p38 , 2004, The Journal of experimental medicine.

[39]  E Bergogne-Bérézin,et al.  Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features , 1996, Clinical microbiology reviews.